Literature DB >> 20395593

Serum osteocalcin is associated with measures of insulin resistance, adipokine levels, and the presence of metabolic syndrome.

Umer Saleem1, Thomas H Mosley, Iftikhar J Kullo.   

Abstract

OBJECTIVE: Osteocalcin has been reported to influence insulin secretion in experimental animals. We investigated whether serum osteocalcin was associated with measures of insulin resistance, circulating adipokine levels, and the presence of metabolic syndrome (MetSyn). METHODS AND
RESULTS: Serum osteocalcin was measured by solid-phase sandwich immunoassay in 1284 blacks (64+/-9 years; 71% women) and 1209 non-Hispanic whites (59+/-10 years; 57% women) belonging to hypertensive sibships. MetSyn was defined per Adult Treatment Panel III criteria. The prevalence of MetSyn was 50% in blacks and 49% in non-Hispanic whites. In each ethnic group, after adjustment for age and gender, osteocalcin levels were inversely correlated with body mass index, fasting glucose and insulin, homeostasis model assessment of insulin resistance, triglycerides, and leptin, and positively correlated with adiponectin (P<0.001 for each variable). In multivariable regression analyses that adjusted for age, gender, smoking, serum creatinine, and statin and estrogen use, osteocalcin levels in the highest quartile (compared with the lowest quartile) were associated with a lower odds ratio (OR) of having MetSyn: OR (95% CI) in blacks, 0.33 (0.23 to 0.46); OR in non-Hispanic whites, 0.43 (0.31 to 0.63).
CONCLUSIONS: Serum osteocalcin is associated with measures of insulin resistance, adipokine levels, and the presence of MetSyn, suggesting a novel cross-talk between bone and adipose tissue.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20395593      PMCID: PMC2939910          DOI: 10.1161/ATVBAHA.110.204859

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  26 in total

Review 1.  Measurement of osteocalcin.

Authors:  A J Lee; S Hodges; R Eastell
Journal:  Ann Clin Biochem       Date:  2000-07       Impact factor: 2.057

2.  Multi-center genetic study of hypertension: The Family Blood Pressure Program (FBPP).

Authors: 
Journal:  Hypertension       Date:  2002-01       Impact factor: 10.190

3.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

4.  The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men.

Authors:  Hanna-Maaria Lakka; David E Laaksonen; Timo A Lakka; Leo K Niskanen; Esko Kumpusalo; Jaakko Tuomilehto; Jukka T Salonen
Journal:  JAMA       Date:  2002-12-04       Impact factor: 56.272

Review 5.  Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition.

Authors:  Scott M Grundy; H Bryan Brewer; James I Cleeman; Sidney C Smith; Claude Lenfant
Journal:  Circulation       Date:  2004-01-27       Impact factor: 29.690

6.  Quantitative insulin sensitivity check index and the reciprocal index of homeostasis model assessment are useful indexes of insulin resistance in type 2 diabetic patients with wide range of fasting plasma glucose.

Authors:  Hisayo Yokoyama; Masanori Emoto; Shigehiko Fujiwara; Koka Motoyama; Tomoaki Morioka; Miyoko Komatsu; Hideki Tahara; Hidenori Koyama; Tetsuo Shoji; Masaaki Inaba; Yoshiki Nishizawa
Journal:  J Clin Endocrinol Metab       Date:  2004-03       Impact factor: 5.958

7.  Sex and ethnic differences in 47 candidate proteomic markers of cardiovascular disease: the Mayo Clinic proteomic markers of arteriosclerosis study.

Authors:  Charles X Kim; Kent R Bailey; George G Klee; Allison A Ellington; Guanghui Liu; Thomas H Mosley; Hamid Rehman; Iftikhar J Kullo
Journal:  PLoS One       Date:  2010-02-05       Impact factor: 3.240

8.  Components of the "metabolic syndrome" and incidence of type 2 diabetes.

Authors:  Robert L Hanson; Giuseppina Imperatore; Peter H Bennett; William C Knowler
Journal:  Diabetes       Date:  2002-10       Impact factor: 9.461

9.  The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity.

Authors:  T Yamauchi; J Kamon; H Waki; Y Terauchi; N Kubota; K Hara; Y Mori; T Ide; K Murakami; N Tsuboyama-Kasaoka; O Ezaki; Y Akanuma; O Gavrilova; C Vinson; M L Reitman; H Kagechika; K Shudo; M Yoda; Y Nakano; K Tobe; R Nagai; S Kimura; M Tomita; P Froguel; T Kadowaki
Journal:  Nat Med       Date:  2001-08       Impact factor: 53.440

10.  Cloning of adiponectin receptors that mediate antidiabetic metabolic effects.

Authors:  Toshimasa Yamauchi; Junji Kamon; Yusuke Ito; Atsushi Tsuchida; Takehiko Yokomizo; Shunbun Kita; Takuya Sugiyama; Makoto Miyagishi; Kazuo Hara; Masaki Tsunoda; Koji Murakami; Toshiaki Ohteki; Shoko Uchida; Sato Takekawa; Hironori Waki; Nelson H Tsuno; Yoichi Shibata; Yasuo Terauchi; Philippe Froguel; Kazuyuki Tobe; Shigeo Koyasu; Kazunari Taira; Toshio Kitamura; Takao Shimizu; Ryozo Nagai; Takashi Kadowaki
Journal:  Nature       Date:  2003-06-12       Impact factor: 49.962

View more
  59 in total

1.  FoxO1 protein cooperates with ATF4 protein in osteoblasts to control glucose homeostasis.

Authors:  Aruna Kode; Ioanna Mosialou; Barbara C Silva; Sneha Joshi; Mathieu Ferron; Marie Therese Rached; Stavroula Kousteni
Journal:  J Biol Chem       Date:  2012-02-01       Impact factor: 5.157

2.  Vitamin D, osteocalcin, and risk for adiposity as comorbidities in middle school children.

Authors:  Claudia Boucher-Berry; Phyllis W Speiser; Dennis E Carey; Steven P Shelov; Siham Accacha; Ilene Fennoy; Robert Rapaport; Yomery Espinal; Michael Rosenbaum
Journal:  J Bone Miner Res       Date:  2012-02       Impact factor: 6.741

Review 3.  Emerging therapeutic opportunities for skeletal restoration.

Authors:  Masanobu Kawai; Ulrike I Mödder; Sundeep Khosla; Clifford J Rosen
Journal:  Nat Rev Drug Discov       Date:  2011-02       Impact factor: 84.694

4.  Osteocalcin levels are inversely associated with Hba1c and BMI in adult subjects with long-standing type 1 diabetes.

Authors:  Ernesto Maddaloni; Luca D'Onofrio; Angelo Lauria; Anna Rita Maurizi; Rocky Strollo; Andrea Palermo; Nicola Napoli; Silvia Angeletti; Paolo Pozzilli; Silvia Manfrini
Journal:  J Endocrinol Invest       Date:  2014-05-24       Impact factor: 4.256

Review 5.  FoxO1, the transcriptional chief of staff of energy metabolism.

Authors:  Stavroula Kousteni
Journal:  Bone       Date:  2011-07-28       Impact factor: 4.398

Review 6.  The role of osteocalcin in the endocrine cross-talk between bone remodelling and energy metabolism.

Authors:  P Ducy
Journal:  Diabetologia       Date:  2011-04-19       Impact factor: 10.122

7.  Bone Mineral Content as a Driver of Energy Expenditure in Prepubertal and Early Pubertal Boys.

Authors:  Lynae J Hanks; Orlando M Gutiérrez; Ambika P Ashraf; Krista Casazza
Journal:  J Pediatr       Date:  2015-04-01       Impact factor: 4.406

Review 8.  Bone as an endocrine organ relevant to diabetes.

Authors:  Sarah L Booth; Amanda J Centi; Caren Gundberg
Journal:  Curr Diab Rep       Date:  2014-12       Impact factor: 4.810

Review 9.  The role of osteoblasts in energy homeostasis.

Authors:  Naomi Dirckx; Megan C Moorer; Thomas L Clemens; Ryan C Riddle
Journal:  Nat Rev Endocrinol       Date:  2019-08-28       Impact factor: 43.330

10.  Carboxylated and uncarboxylated forms of osteocalcin directly modulate the glucose transport system and inflammation in adipocytes.

Authors:  H S Hill; J Grams; R G Walton; J Liu; D R Moellering; W T Garvey
Journal:  Horm Metab Res       Date:  2014-02-19       Impact factor: 2.936

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.